1319 ET - Bicycle Therapeutics takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included "a significant proportion of unconfirmed responses," and while the data are early, he says the effectiveness appears to be "somewhat underwhelming," when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries "an inherent risk of data mining." The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
December 13, 2024 13:19 ET (18:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。